Semaglutide Poison Control Calls Surge After 2021 FDA Weight-Loss Approval, Study Finds
Study links FDA weight-loss approval to a surge in semaglutide poison control calls; dosing mistakes and wider use prompt calls for better patient education.
The number of semaglutide poison control calls in the United States rose sharply after the Food and Drug Administration approved semaglutide for chronic weight management in 2021, according to a new data analysis by researchers at the University of Texas at San Antonio. The study, led by undergraduate researcher Jordan Miller with mentorship from Professor David Han, found the volume and pattern of calls changed markedly as semaglutide moved from a diabetes treatment to a broadly used weight-loss medication. Investigators say many incidents reflected preventable dosing errors as the drug reached a larger, less medically experienced population.
Data Shows Rapid Increase in GLP-1RA Calls
The researchers analyzed national poison control center records covering the years before and after the 2021 approval of semaglutide for weight management. Prior to mid-2021, poison centers typically recorded between 1,000 and 1,500 calls related to GLP-1 receptor agonists annually. That count nearly doubled soon after approval and climbed to more than 8,000 calls by 2023, the study reports. Semaglutide accounted for a disproportionate share of the increase compared with other drugs in the same class.
Team and Methodology Behind the Findings
Miller conducted the analysis through the Provost’s Undergraduate Research Fellowship and worked with medical and toxicology specialists at UT San Antonio’s Long School of Medicine, including Robert S. Miller, Pharm.D., and Shawn M. Varney, M.D. Professor David Han supervised the project from the Department of Statistics & Data Science. The multidisciplinary team compared call volumes, drug-specific trends and the nature of reported exposures to determine whether the increase was temporally associated with the FDA’s decision to expand semaglutide’s indication.
Nature of Calls Points to Dosing and Handling Errors
A significant portion of reported incidents involved accidental dosing or therapeutic mistakes rather than deliberate misuse. Two frequent errors emerged: patients administering semaglutide daily instead of the recommended once-weekly schedule, and initiating therapy at higher doses rather than following the advised stepwise titration. Investigators noted that semaglutide dosing requires both a weekly interval and gradual dose escalation, making the regimen unfamiliar to many new users. The data indicate these misunderstandings contributed substantially to the rise in poison control inquiries.
Researchers Say Approval Was a Turning Point
According to the team, the FDA approval for weight management represented a clear inflection point in how semaglutide was used and who was taking it. Where earlier use was largely among people treated for type 2 diabetes, approval opened the drug to a much broader population seeking weight loss. “We needed to quantify whether the surge in calls stemmed directly from the approval and the expansion of use,” Professor Han said, explaining the impetus for the analysis. The study authors argue the evidence supports a causal link between expanded approval, rapid uptake, and the observed increase in poison center activity.
Calls for Improved Patient Education and Safeguards
The authors recommend strengthening education across the prescribing pathway to reduce preventable errors. They advise clearer instructions at prescriber visits, reinforced counseling at the pharmacy counter, and standardized materials explaining weekly dosing and stepwise titration. Clinicians and pharmacists were urged to confirm patient understanding of injection schedules and starting doses, and to consider follow-up touchpoints during the initial weeks of therapy. The researchers emphasized that many of the reported exposures likely could have been avoided with these basic safety measures.
Recognition and Publication of the Work
Miller presented the study at UT San Antonio’s Los Datos conference, where the project received top honors. The analysis has also been published in peer-reviewed outlets and featured in professional statistical and toxicology forums, increasing its visibility to clinicians, data scientists and public health officials. The research team highlighted the role of statistical analysis in converting large administrative datasets into actionable public health insights that can inform education and policy.
The study’s findings arrive amid intense public interest in GLP-1 receptor agonists such as semaglutide, both as treatments for diabetes and as widely adopted weight-loss agents. Researchers cautioned that while semaglutide can offer clinical benefits when used correctly, its expanding use outside traditional diabetes care requires careful attention to dosing instructions and patient support to prevent avoidable harms.
Wider availability and media coverage have made semaglutide a household name, but the researchers said awareness has outpaced practical understanding for many new users. They concluded that coordinated efforts by prescribers, pharmacists and poison control networks to deliver clear, consistent dosing guidance could curb the trend in unnecessary exposures and improve patient safety.
